Daily Stock Analysis, ICPT, Intercept Pharmaceuticals Inc, priceseries

Intercept Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
90.66
Close
91.23
High
92.00
Low
87.70
Previous Close
90.53
Daily Price Gain
0.70
YTD High
131.87
YTD High Date
Feb 19, 2019
YTD Low
85.05
YTD Low Date
Apr 22, 2019
YTD Price Change
-6.02
YTD Gain
-6.19%
52 Week High
133.74
52 Week High Date
Oct 1, 2018
52 Week Low
64.50
52 Week Low Date
Apr 25, 2018
52 Week Price Change
25.08
52 Week Gain
37.91%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 19. 2018
57.72
Jan 31. 2018
62.71
8 Trading Days
8.65%
Link
LONG
Apr 3. 2018
62.83
Apr 19. 2018
69.57
12 Trading Days
10.73%
Link
LONG
Jun 29. 2018
83.91
Jul 16. 2018
93.41
10 Trading Days
11.32%
Link
LONG
Oct 31. 2018
96.01
Nov 12. 2018
103.99
8 Trading Days
8.31%
Link
LONG
Jan 4. 2019
102.35
Jan 29. 2019
113.52
16 Trading Days
10.92%
Link
LONG
Mar 11. 2019
104.85
Mar 22. 2019
110.85
9 Trading Days
5.72%
Link
Company Information
Stock Symbol
ICPT
Exchange
NasdaqGS
Company URL
http://www.interceptpharma.com
Company Phone
646-747-1000
CEO
Mark E. Pruzanski
Headquarters
New York
Business Address
450 W. 15TH STREET, SUITE 505, NEW YORK, NY 10011
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001270073
About

Intercept Pharmaceuticals is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.

Description

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. Its lead product candidate is obeticholic acid (OCA), a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). The company is developing OCA to treat various non-viral progressive liver diseases, such as nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. It also provides OCA under the Ocaliva brand name for the treatment of primary biliary cholangitis in the United States and Europe. In addition, the company is developing INT-767, an orally administered dual FXR and TGR5 agonist for the treatment of liver fibrosis; and INT-777, an orally administered TGR5 agonist for the treatment of type 2 diabetes, associated metabolic disorders, and other gastrointestinal indications. Intercept Pharmaceuticals, Inc. was founded in 2002 and is headquartered in New York, New York.